Celldexs anti-cKIT antibody proves it can reduce chronic hives in another phase 2 trial

### Title
Celldex's Anti-cKIT Antibody Shows Promise in Reducing Chronic Hives in Phase 2 Trial
### Keywords
- Celldex Therapeutics
- Anti-cKIT antibody
- Chronic hives
- Phase 2 trial
- Urticaria
### Key Facts
1. Celldex's Anti-cKIT Antibody Success: Celldex Therapeutics' anti-cKIT antibody has shown positive results in reducing chronic hives in a phase 2 trial, following a previous mid-phase trial in chronic spontaneous urticaria.
2. Phase 2 Trial Results: The latest phase 2 trial demonstrated the antibody's ability to reduce hives, building on the success of the previous trial in November 2023.
3. Mechanism of Action: The anti-cKIT antibody targets the cKIT receptor, which is involved in mast cell activation, a key factor in urticaria.
4. Potential Treatment Option: This antibody may offer a new treatment option for chronic spontaneous urticaria, which has significant unmet clinical needs.
5. Ongoing Research: The study is part of ongoing research into novel therapeutic approaches for urticaria, including mast cell silencing and other targeted therapies.